ZBIO

Zenas Biopharma Inc

Add to Watchlist

Advanced Chart

16.440

+0.78(4.981%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

16.620

Open

15.620

VWAP

Vol

120.25K

Mkt Cap

655.12M

Low

15.250

Amount

EV/EBITDA(TTM)

Total Shares

41.83M

342.74M

EV/OCF(TTM)

P/S(TTM)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

4 Analyst Rating

102.25% Upside

Wall Street analysts forecast ZBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBIO is 33.25 USD with a low forecast of 27.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

102.25% Upside

Current: 16.440

Low

27.00

Averages

33.25

High

45.00

102.25% Upside

Current: 16.440

Low

27.00

Averages

33.25

High

45.00

Morgan Stanley

Overweight

Buy

downgrade

$35 -> $31

2025-07-03

Reason

Morgan Stanley

Price Target

$35 -> $31

2025-07-03

downgrade

Overweight

Buy

Reason

Morgan Stanley assumed coverage of Zenas BioPharma with an Overweight rating with a price target of $31, down from $35. Upcoming readouts in 4Q25 the first half of 2026 could demonstrate the potential of inhibiting B cells in autoimmune conditions while building out the pipeline-in-a-product potential of obexelima, the analyst tells investors in a research note.

Wedbush

Martin Fan

Buy

Initiates

$35

2025-03-20

Reason

Wedbush

Martin Fan

Price Target

$35

2025-03-20

Initiates

Buy

Reason

Wedbush initiated coverage of Zenas BioPharma with an Outperform rating and $35 price target.

Guggenheim

Yatin Suneja

Strong Buy

Reiterates

$45

2025-03-12

Reason

Guggenheim

Yatin Suneja

Price Target

$45

2025-03-12

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$30

2025-03-12

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$30

2025-03-12

Reiterates

Strong Buy

Reason

Wolfe Research

Andy Chen

Buy

Initiates

$19

2025-02-04

Reason

Wolfe Research

Andy Chen

Price Target

$19

2025-02-04

Initiates

Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Initiates

$30

2024-12-16

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$30

2024-12-16

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Zenas Biopharma Inc (ZBIO.O) is -3.79, compared to its 5-year average forward P/E of -2.46. For a more detailed relative valuation and DCF analysis to assess Zenas Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.46

Current PE

-3.79

Overvalued PE

-1.32

Undervalued PE

-3.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.81

Current EV/EBITDA

-1.84

Overvalued EV/EBITDA

1.19

Undervalued EV/EBITDA

-2.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

48.05

Current PS

182.06

Overvalued PS

104.45

Undervalued PS

-8.34

Financials

Annual

Quarterly

FY2025Q1

10.00M

Total Revenue

FY2025Q1

YoY :

+35.36%

-37.33M

Operating Profit

FY2025Q1

YoY :

+20.77%

-33.57M

Net Income after Tax

FY2025Q1

YoY :

+14.29%

-0.80

EPS - Diluted

FY2025Q1

YoY :

+93.83%

-37.07M

Free Cash Flow

FY2025Q1

100.00

Gross Profit Margin - %

FY2025Q1

N/A

FCF Margin - %

FY2025Q1

-335.73

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

244.3K

USD

Months

6-9

867.0K

USD

Months

0-12

66.9M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

436.9K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

615.0K

Volume

Months

6-9

450.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

244.3K

USD

Months

6-9

867.0K

USD

Months

0-12

66.9M

USD

Months

ZBIO News & Events

Events Timeline

2025-05-15 (ET)

2025-05-15

07:15:01

Zenas BioPharma reports Q1 EPS (80c) vs ($17.89) last year

2025-04-07 (ET)

2025-04-07

07:14:02

Zenas BioPharma appoints Haley Laken as CSO

2025-03-17 (ET)

2025-03-17

07:09:28

Zenas BioPharma appoints Lisa von Moltke as Head of R&D, CMO

News

8.0

06-20Yahoo Finance

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

7.0

06-16PRnewswire

June 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIO

7.0

06-16Globenewswire

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

People Also Watch

Radiant Logistics Inc

Manitowoc Company Inc

CompX International Inc

Logistic Properties of The Americas

Mayville Engineering Company Inc

Ares Commercial Real Estate Corp

4.590

USD

-1.50%

FAQ

What is Zenas Biopharma Inc (ZBIO) stock price today?

The current price of ZBIO is 16.44 USD — it has increased 4.98 % in the last trading day.

ZBIO

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ZBIO News & Events

Events Timeline

News

People Also Watch

FAQ

What is Zenas Biopharma Inc (ZBIO) stock price today?

What is Zenas Biopharma Inc (ZBIO)'s business?

What is the price predicton of ZBIO Stock?

What is Zenas Biopharma Inc (ZBIO)'s revenue for the last quarter?

What is Zenas Biopharma Inc (ZBIO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Zenas Biopharma Inc (ZBIO)'s fundamentals?

How many employees does Zenas Biopharma Inc (ZBIO). have?

What is Zenas Biopharma Inc (ZBIO) market cap?